{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:38:00Z","timestamp":1786653480958,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"\n Introduction:<\/jats:title>\n Hypertrophic cardiomyopathy (HCM), the most common inherited cardiomyopathy, has significant clinical presentation and outcome diversity. Early diagnosis and proper management are essential to improve the patient\u2019s quality of life and prevent sudden cardiac death. Collecting patient information in each country is the first step in finding the gaps in the proper diagnosis and management of these patients. We aimed to determine the general characteristics of HCM in the largest referral tertiary heart center in Iran.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n In this cross-sectional study, between 2016 and 2020, clinical, imaging, and therapeutic data of patients diagnosed with HCM at Rajaie Cardiovascular Medical Research Center were reviewed and followed up to 48 months for Major adverse cardiovascular events (MACE), defined as composite endpoint of death, stroke (nonfatal), hospitalization due to decompensated heart failure (HF) and malignant ventricular arrhythmia defined as sustained ventricular tachycardia or ventricular fibrillation.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 322 patients, with a mean age of 49.7 \u00b1 1 years, including 129 women (40%), were studied. Women were significantly older than men (53.1 \u00b1 9.1 vs. 47.2 \u00b1 8.9,\n P<\/jats:italic>\n < 0.0001). The most prevalent symptom was dyspnea on exertion, affecting 158 patients (49%). Nonobstructive HCM was present in 180 patients (55.9%), and atrial fibrillation was observed in 82 patients (25.46%). Major Adverse Cardiovascular Events were more frequent in patients with obstructive forms of the disease. Beta-receptor-blocking agents were the most used medication (85%). In addition, 29 patients (9% overall and 20.4% of those with obstructive forms) were treated with disopyramide, and 19 patients (5.9%) underwent surgical myectomy. Late gadolinium enhancement (LGE) was detected in 56 out of 122 patients (45.9%) who underwent cardiac magnetic resonance imaging. MACE incidence was notably higher in patients with positive LGE. Overall, MACE occurred in 110 patients (34.16%). Malignant ventricular arrhythmias were reported in 64 patients (19.87%), HF in 36 patients (11.18%), and HCM-related death in 4 patients (1.24%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n This study showed the general characteristics, clinical outcomes, and therapeutic approach of HCM patients in Iran. We found more MACE in obstructive versus nonobstructive forms and LGE \u2265 10%. Disopyramide and implantable cardioverter-defibrillator implantation are well-adapted therapeutic options, followed by surgical myectomy. However, genetic testing and alcohol septal ablation are uncommon procedures.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/heartviews.heartviews_155_24","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:00:37Z","timestamp":1759341637000},"page":"88-95","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hypertrophic Cardiomyopathy in Iran: General Characteristics, Clinical Presentations, Imaging Features, and Major Adverse Cardiovascular Events of 322 Patients"],"prefix":"10.4103","volume":"26","author":[{"given":"Saman","family":"Rostambeigi","sequence":"first","affiliation":[{"name":"Rajaie Cardiovascular, Medical, and Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin Mahmoudi","family":"Hamidabad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Rasoul-E-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nadri","sequence":"additional","affiliation":[{"name":"Rajaie Cardiovascular, Medical, and Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Alizadehasl","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Department and Research Center, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Hashemi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Babol University of Medical Sciences, Babol, Mazandaran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Pouraliakbar","sequence":"additional","affiliation":[{"name":"Rajaie Cardiovascular, Medical, and Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Sadeghpour","sequence":"additional","affiliation":[{"name":"MedStar, Cardiovascular Core Laboratory, Georgetown University, MedStar Health Research Institute, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"R1-20251007","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R2-20251007","first-page":"e558","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"R3-20251007","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/eurheartj\/ehp307","article-title":"Sudden cardiac death risk in hypertrophic cardiomyopathy","volume":"30","author":"Ommen","year":"2009","journal-title":"European Heart Journal"},{"key":"R4-20251007","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","article-title":"Hypertrophic cardiomyopathy: A systematic review","volume":"287","author":"Maron","year":"2002","journal-title":"JAMA"},{"key":"R5-20251007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamacardio.2019.4638","article-title":"Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy","volume":"5","author":"Eberly","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R6-20251007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"R7-20251007","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"R8-20251007","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R9-20251007","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","article-title":"Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy","volume":"46","author":"Olivotto","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R10-20251007","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9149(03)00266-2","article-title":"Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy","volume":"91","author":"Maron","year":"2003","journal-title":"Am J Cardiol"},{"key":"R11-20251007","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20251007","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"R13-20251007","first-page":"203","article-title":"Romanian registry of hypertrophic cardiomyopathy \u2013 Overview of general characteristics and therapeutic choices at a national level","volume":"56","author":"Ionil\u0103","year":"2018","journal-title":"Rom J Intern Med"},{"key":"R14-20251007","doi-asserted-by":"crossref","first-page":"e007537","DOI":"10.1161\/CIRCHEARTFAILURE.120.007537","article-title":"Clinical profile and health disparities in a multiethnic cohort of patients with hypertrophic cardiomyopathy","volume":"14","author":"Butters","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R15-20251007","doi-asserted-by":"crossref","first-page":"e007230","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230","article-title":"Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: An analysis of the international sarcomeric human cardiomyopathy registry","volume":"13","author":"Canepa","year":"2020","journal-title":"Circ Heart Fail"},{"key":"R16-20251007","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-20251007","first-page":"1994","article-title":"Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery","volume":"38","author":"Qin","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R18-20251007","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/0735-1097(90)92820-R","article-title":"Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy","volume":"15","author":"Spirito","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"R19-20251007","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N Engl J Med"},{"key":"R20-20251007","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","article-title":"Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy","volume":"357","author":"Elliott","year":"2001","journal-title":"Lancet"},{"key":"R21-20251007","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.104.507723","article-title":"Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy","volume":"112","author":"Rickers","year":"2005","journal-title":"Circulation"},{"key":"R22-20251007","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCIMAGING.112.972760","article-title":"Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy","volume":"5","author":"Maron","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"R23-20251007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2010.05.007","article-title":"Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy","volume":"56","author":"Bruder","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R24-20251007","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcmg.2011.11.021","article-title":"Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy","volume":"5","author":"Green","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"R25-20251007","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"R26-20251007","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"R27-20251007","doi-asserted-by":"crossref","first-page":"e001267","DOI":"10.1136\/bmjopen-2012-001267","article-title":"Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: A retrospective database analysis","volume":"2","author":"Biagini","year":"2012","journal-title":"BMJ Open"},{"key":"R28-20251007","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0735-1097(03)00854-4","article-title":"Myocardial bridging in adult patients with hypertrophic cardiomyopathy","volume":"42","author":"Sorajja","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R29-20251007","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/eurheartj\/ehp121","article-title":"Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death","volume":"30","author":"Basso","year":"2009","journal-title":"Eur Heart J"},{"key":"R30-20251007","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0735-1097(00)00987-6","article-title":"Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease","volume":"36","author":"Mohiddin","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R31-20251007","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R32-20251007","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/eurheartj\/ehq308","article-title":"Sudden death in hypertrophic cardiomyopathy: Old risk factors re-assessed in a new model of maximalized follow-up","volume":"31","author":"Dimitrow","year":"2010","journal-title":"Eur Heart J"},{"key":"R33-20251007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2020.11.001","article-title":"Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis","volume":"66","author":"Kamp","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"key":"R34-20251007","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Views"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_155_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:08Z","timestamp":1786649888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_155_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/heartviews.heartviews_155_24","relation":{},"ISSN":["1995-705X","0976-5123"],"issn-type":[{"value":"1995-705X","type":"print"},{"value":"0976-5123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}